Previous 10 | Next 10 |
Investing in biotechnology companies is both difficult and incredibly exciting. Watching as a company goes through the regulatory approval process, from a fledgling early-stage clinical trial biotech to an industry juggernaut, can be exhilarating. While positive outcomes aren't guarante...
The following slide deck was published by NovoCure Limited in conjunction with this event. For further details see: NovoCure (NVCR) Investor Presentation - Slideshow
Novocure (NASDAQ: NVCR) today announced 19 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2022, to be held in New Orleans from April 8 to April 13, 2022. The research described in the presentation...
With its novel Tumor Treating Fields therapy that uses electrical pulses to treat cancer, Novocure (NASDAQ: NVCR) could offer new hope to patients and physicians. In this Motley Fool Live segment from The Pharma & Biotech Show, recorded on March 23 , Fool.com contributor...
One group stands out as an interesting and potentially dramatically undervalued area of the market in the wake of the pandemic and its historical footprint: Medical device stocks. The healthcare system has been forever changed by the pandemic, which accelerated several core healthcare industr...
Biotech stocks, in general, again performed dismally in the first quarter of 2022. However, there are some signs of improvement. The lower valuations could present a great buying opportunity once the inevitable strong rebound materializes. We asked three Motley Fool contributors which b...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2022 on Thursday, April 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the thr...
Novocure (NASDAQ: NVCR) could either be a big win or a deep dip for investors. In this clip from "3 Minute Stocks Updates" on Motley Fool Live , recorded on March 2 , Motley Fool contributor Brian Feroldi discusses the reasons why this medical device stock could go either wa...
Patients in phase 2 pilot trial 2-THE-TOP had median progression-free survival of 12.1 months compared with 7.9 months for matched-control patients from EF-14 Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Oncology at the McKnight...
An independent data monitoring has recommended that a phase 3 trial of Novocure's (NASDAQ:NVCR) Tumor Treating Fields (TTFs) for ovarian cancer should continue following an interim analysis. The analysis showed that an increase in sample size is not necessary and the committee recommended tha...
News, Short Squeeze, Breakout and More Instantly...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...
2024-06-13 14:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-04 10:45:03 ET Wells Fargo analyst issues NEUTRAL recommendation for NVCR on June 4, 2024 09:01AM ET. The previous analyst recommendation was Neutral. NVCR was trading at $24.055 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...